Difficulty: Medium
Average Score: 77%
Practice
An epileptic woman controlled by phenytoin therapy conceives. Which of the following measures is most appropriate?
Correct answer
C
Rationale
In this scenario, the most appropriate measure for an epileptic woman controlled by phenytoin therapy who conceives is to gradually reduce the phenytoin dose to the lowest effective level (Option C). This approach is crucial because abrupt discontinuation of phenytoin can lead to seizures, posing risks to both the mother and the fetus. By gradually tapering the dose to the lowest effective level, the woman can maintain seizure control while minimizing potential harm to the developing fetus.
Option A, medical termination of pregnancy, is not the most appropriate measure as it does not address the management of the woman's epilepsy during pregnancy. Pregnancy termination should not be the default response to a woman with epilepsy on phenytoin therapy.
Option B, withdrawing phenytoin therapy, is not recommended as sudden withdrawal can result in an increased risk of seizures, which can be harmful to both the mother and the fetus. It is essential to maintain seizure control during pregnancy to ensure the well-being of both the mother and the developing baby.
Option D, substituting phenytoin with a combination of carbamazepine and sodium valproate, is not the best course of action without a clear indication. Changing the antiepileptic medication regimen during pregnancy should be done cautiously and only if necessary, as each medication carries its own risks and benefits during pregnancy.
Educationally, this question highlights the importance of managing epilepsy in pregnant women, emphasizing the need for individualized care that balances seizure control with minimizing risks to the developing fetus. Gradually reducing phenytoin dosage is a safe and effective strategy in this context, showcasing the significance of understanding pharmacological management in special populations like pregnant women with epilepsy.
Option A, medical termination of pregnancy, is not the most appropriate measure as it does not address the management of the woman's epilepsy during pregnancy. Pregnancy termination should not be the default response to a woman with epilepsy on phenytoin therapy.
Option B, withdrawing phenytoin therapy, is not recommended as sudden withdrawal can result in an increased risk of seizures, which can be harmful to both the mother and the fetus. It is essential to maintain seizure control during pregnancy to ensure the well-being of both the mother and the developing baby.
Option D, substituting phenytoin with a combination of carbamazepine and sodium valproate, is not the best course of action without a clear indication. Changing the antiepileptic medication regimen during pregnancy should be done cautiously and only if necessary, as each medication carries its own risks and benefits during pregnancy.
Educationally, this question highlights the importance of managing epilepsy in pregnant women, emphasizing the need for individualized care that balances seizure control with minimizing risks to the developing fetus. Gradually reducing phenytoin dosage is a safe and effective strategy in this context, showcasing the significance of understanding pharmacological management in special populations like pregnant women with epilepsy.